Tabu Kazuaki, Mawatari Seiichi, Oda Kohei, Taniyama Ohki, Toyodome Ai, Ijuin Sho, Sakae Haruka, Kumagai Kotaro, Kanmura Shuji, Ido Akio
Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.
Mol Clin Oncol. 2021 Sep;15(3):174. doi: 10.3892/mco.2021.2336. Epub 2021 Jun 29.
Highly sensitive agglutinin-reactive fraction of α-fetoprotein (hs-AFP-L3) is a specific marker for hepatocellular carcinoma (HCC) and has been reliable in cases with a low serum α-fetoprotein (AFP) level. However, the biomarkers that contribute to hepatocarcinogenesis during the long-term observation are not yet clear. The present study reported the clinical utility of hs-AFP-L3 in the long-term observation of patients with chronic liver disease. The subjects were 106 patients with chronic liver disease without HCC or a history of HCC treatment and who had been followed for >12 months. hs-AFP-L3 was measured using cryopreserved serum. The factors contributing to hepatocarcinogenesis were examined using univariate and multivariate analyses. The median observation period was 88 months (15-132 months). The cumulative incidence of HCC was 10.5% at 5 years and 19.6% at 10 years. The univariate analysis revealed that age ≥55 years old, platelet count ≤13.1x10/µl, hyaluronic acid ≥80.8 ng/ml, alanine transaminase ≥47 U/l, AFP ≥6.3 ng/ml, hs-AFP-L3 ≥3.5% and des-γ-carboxy prothrombin (DCP) ≥25 mAU/ml were significant factors. In the multivariate analysis, platelet count ≤13.1x10/µl [hazard ratio (HR), 4.966; 95% confidence interval (CI), 1.597-15.437; P=0.006] and hs-AFP-L3 ≥3.5% (HR, 5.450; 95% CI, 1.522-19.512; P=0.009) were extracted as significant factors contributing to hepatocarcinogenesis. In addition, for cases with AFP <20 ng/ml, a multivariate analysis revealed that hs-AFP-L3 ≥4.9% (HR, 11.608; 95% CI, 2.422-55.629; P=0.002) and DCP ≥25 mAU/ml (HR, 3.936; 95% CI, 1.088-14.231; P=0.037) were significant factors contributing to hepatocarcinogenesis. hs-AFP-L3 is a useful marker for predicting hepatocarcinogenesis in the long-term observation of patients with chronic liver disease.
甲胎蛋白的高敏凝集素反应性组分(hs-AFP-L3)是肝细胞癌(HCC)的特异性标志物,在血清甲胎蛋白(AFP)水平较低的病例中也很可靠。然而,在长期观察过程中促成肝癌发生的生物标志物尚不清楚。本研究报告了hs-AFP-L3在慢性肝病患者长期观察中的临床应用价值。研究对象为106例无HCC或HCC治疗史且随访时间超过12个月的慢性肝病患者。使用冻存血清检测hs-AFP-L3。通过单因素和多因素分析研究促成肝癌发生的因素。中位观察期为88个月(15 - 132个月)。HCC的5年累积发病率为10.5%,10年累积发病率为19.6%。单因素分析显示,年龄≥55岁、血小板计数≤13.1×10⁴/µl、透明质酸≥80.8 ng/ml、丙氨酸转氨酶≥47 U/l、AFP≥6.3 ng/ml、hs-AFP-L3≥3.5%以及异常凝血酶原(DCP)≥25 mAU/ml是显著因素。多因素分析中,血小板计数≤13.1×10⁴/µl [风险比(HR),4.966;95%置信区间(CI),1.597 - 15.437;P = 0.006]和hs-AFP-L3≥3.5%(HR,5.450;95% CI,1.522 - 19.512;P = 0.009)被确定为促成肝癌发生的显著因素。此外,对于AFP < 20 ng/ml的病例,多因素分析显示hs-AFP-L3≥4.9%(HR,11.608;95% CI,2.422 - 55.629;P = 0.002)和DCP≥25 mAU/ml(HR,3.936;95% CI,1.088 - 14.231;P = 0.037)是促成肝癌发生的显著因素。hs-AFP-L3是预测慢性肝病患者长期观察中肝癌发生的有用标志物。